Submit your application here www.wapg.link/AbbVie
All submissions must be received by 22nd May 2022 11:59pm BST.
All submissions must be received by 22nd May 2022 11:59pm BST.
AbbVie is excited to launch the 2022 AbbVie UK Golden Ticket in collaboration with We Are Pioneer Group (WAPG), the UK’s largest ecosystem provider for science and innovation businesses, to support the thriving UK life sciences start-up community.
For AbbVie, this demonstrates our commitment to investing in the UK’s world class life sciences sector and accelerating the delivery of life-changing innovations to patients
The Golden Ticket programme awards one year of free-lab space, funded by AbbVie, and access to core facilities and services at selected WAPG locations*, membership to the WAPG community of scientists, technologists and entrepreneurs, and support from AbbVie’s world leading global scientists, business leaders and mentors.
AbbVie will grant one Golden Ticket to an early-stage UK life science biotech company in 2022.
* BioCity Glasgow, Wilton Centre (Redcar), BioCity Nottingham, Colworth Park (Bedfordshire), Kent Science Park.
AbbVie is looking for early-stage biotech companies that fit the following criteria:
* BioCity Glasgow, Wilton Centre (Redcar), BioCity Nottingham, Colworth Park (Bedfordshire), Kent Science Park.
Submit your application here www.wapg.link/AbbVie. Please note this link will take you to the We Are Pioneer Group Website which is not owned by AbbVie.
All submissions must be received by 22nd May 2022 11:59pm BST. Applicants may only submit one entry each.
Please include the following in your application:
AbbVie leaders who are qualified scientific experts in respective fields, including specialties in scientific and/or medical research and business, will review all submissions. The following criteria will form application judging criteria:
The AbbVie Golden Ticket programme awards early-stage life science companies or biotech start-ups with one year free lab and office space at selected We Are Pioneer Group (WAPG) locations* for one year.
The value of a Golden Ticket prepays the cost of one (1) lab bench, one (1) desk and WAPG membership for one (1) person for one (1) year. If no benches are available at the selected site the value of the Golden Ticket will be extended while the company remains on the waitlist for a bench. In addition recipeints receive access to core facilities and services at selected WAPG locations, membership to the WAPG community of scientists, technologists and entrepreneurs, and support from AbbVie’s world leading global scientists, business leaders and mentors.
The winner will receive priority admission or renewal for one year’s use of a lab bench and access to shared facilities at a selected WAPG location, as well as opportunities to engage with AbbVie scientific and business executives.
* BioCity Glasgow, Wilton Centre (Redcar), BioCity Nottingham, Colworth Park (Bedfordshire), Kent Science Park.
Golden Tickets may be awarded to either startup companies that are interested in joining the WAPG Community or current Resident Companies.
To be eligible to participate to have the opportunity to receive the Award, the Applicant must: (1) be an independent legal entity (SME); (2) not have raised more than £5M GBP before receiving the Golden Ticket; (3) submit a complete Application; (4) represent and warrant that the Applicant has read and agrees to abide by all requirements of these Rules; (5) not be affiliated with or employed by AbbVie or WAPG including as an employee, contractor, officer or director of AbbVie or WAPG and including as an immediate family member of AbbVie or WAPG (including parents, spouses, children, siblings or any individual residing in the household of a AbbVie, officer or director (whether or not related)); and (6) not be an academic institution such as a college, university or school.
Diagnostics, Devices, Research Tools, and Healthcare-Services & IT companies are excluded.
The 2022 AbbVie Golden Ticket winner will be chosen by a team of AbbVie’s scientific and business leaders and will be based on the strength and novelty of the scientific rationale, and the potential to transform patient care.
The top 4-5 proposals (semi-finalists) will be invited to a final pitch virtual presentation in June 2022.
Companies must be financially and scientifically ready to move into a selected WAPG location* within two to six months of receiving the ticket and to execute on the submitted research plan.
* BioCity Glasgow, Wilton Centre (Redcar), BioCity Nottingham, Colworth Park (Bedfordshire), Kent Science Park.
Please refer to our Therapeutic Focus Areas:
https://www.abbvie.co.uk/our-science/therapeutic-focus-areas.html
For more information and to apply visit www.wapg.link/AbbVie. Please note this link will take you to the We Are Pioneer Group Website which is not owned by AbbVie.